PARP Inhibitor

COPENHAGEN, Denmark, June 18, 2026 Allarity Therapeutics, Inc. announced the presentation of a Trial-in-Progress poster for its ongoing Phase...

SALT LAKE CITY, March 17, 2026 Myriad Genetics, Inc. announced that the U.S. Food and Drug Administration (FDA) has...

NEW YORK, March 19, 2026 Pfizer Inc. announced that its Phase 3 TALAPRO-3 clinical trial evaluating TALZENNA® (talazoparib) in...

TARPON SPRINGS, Fla., March 6, 2026 Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced the successful closing of...